These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 20654981)

  • 1. [Tolerance of biological agents in children].
    Bader-Meunier B
    Arch Pediatr; 2010 Jun; 17(6):962-3. PubMed ID: 20654981
    [No Abstract]   [Full Text] [Related]  

  • 2. Occurrence of inflammatory bowel disease in four patients with juvenile idiopathic arthritis receiving etanercept or infliximab.
    Tarkiainen M; Tynjälä P; Vähäsalo P; Lahdenne P
    Scand J Rheumatol; 2011 Mar; 40(2):150-2. PubMed ID: 20868307
    [No Abstract]   [Full Text] [Related]  

  • 3. Adalimumab in juvenile rheumatoid arthritis.
    Taddio A; Marchetti F
    N Engl J Med; 2008 Dec; 359(23):2495-6; author reply 2496-7. PubMed ID: 19065749
    [No Abstract]   [Full Text] [Related]  

  • 4. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
    Otten MH; Prince FH; Twilt M; Ten Cate R; Armbrust W; Hoppenreijs EP; Koopman-Keemink Y; Wulffraat NM; Gorter SL; Dolman KM; Swart JF; van den Berg JM; van Rossum MA; van Suijlekom-Smit LW
    J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lack of adverse effect of anti-tumor necrosis factor-α biologics in treatment of rheumatoid arthritis: 5 years follow-up.
    Dewedar AM; Shalaby MA; Al-Homaid S; Mahfouz AM; Shams OA; Fathy A
    Int J Rheum Dis; 2012 Jun; 15(3):330-5. PubMed ID: 22709496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tumor necrosis factor blockers in rheumatoid arthritis.
    Pisetsky DS
    N Engl J Med; 2000 Mar; 342(11):810-1. PubMed ID: 10717018
    [No Abstract]   [Full Text] [Related]  

  • 7. Tumor necrosis factor antagonists in the therapy of psoriasis.
    Mössner R; Schön MP; Reich K
    Clin Dermatol; 2008; 26(5):486-502. PubMed ID: 18755367
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of tumor necrosis factor inhibitors in acute generalized pustular psoriasis.
    Viguier M; Aubin F; Delaporte E; Pagès C; Paul C; Beylot-Barry M; Goujon C; Rybojad M; Bachelez H;
    Arch Dermatol; 2012 Dec; 148(12):1423-5. PubMed ID: 23247492
    [No Abstract]   [Full Text] [Related]  

  • 9. Infections during treatment with biological agents and possible treatment in clinical practice.
    Atzeni F; Benucci M; Sarzi-Puttini P
    Expert Rev Clin Immunol; 2013 Mar; 9(3):193-5. PubMed ID: 23445193
    [No Abstract]   [Full Text] [Related]  

  • 10. Persistence of Staphylococcus aureus colonization among individuals with immune-mediated inflammatory diseases treated with TNF-α inhibitor therapy.
    Varley CD; Deodhar AA; Ehst BD; Bakke A; Blauvelt A; Vega R; Yamashita S; Winthrop KL
    Rheumatology (Oxford); 2014 Feb; 53(2):332-7. PubMed ID: 24173434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Introduction to biological drugs].
    Fernández-Cruz E; Alecsandru D; Rodríguez-Sainz C
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():2-6. PubMed ID: 19080985
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous sarcoidosis occurring during anti-TNF-alpha treatment: report of two cases.
    Dhaille F; Viseux V; Caudron A; Dadban A; Tribout C; Boumier P; Clabaut A; Lok C
    Dermatology; 2010; 220(3):234-7. PubMed ID: 20185892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Five cases of anti-tumor necrosis factor alpha-induced psoriasis presenting with severe scalp involvement in children.
    Perman MJ; Lovell DJ; Denson LA; Farrell MK; Lucky AW
    Pediatr Dermatol; 2012; 29(4):454-9. PubMed ID: 21995665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Advertisements for TNF Inhibitors.
    Med Lett Drugs Ther; 2008 Nov; 50(1299):89. PubMed ID: 19008788
    [No Abstract]   [Full Text] [Related]  

  • 15. Successful rapid rituximab desensitization for hypersensitivity reactions to monoclonal antibodies in a patient with rheumatoid arthritis: a remarkable option.
    Abadoglu O; Epozturk K; Atayik E; Kaptanoglu E
    J Investig Allergol Clin Immunol; 2011; 21(4):319-21. PubMed ID: 21721382
    [No Abstract]   [Full Text] [Related]  

  • 16. Tumor necrosis factor inhibitors for rheumatoid arthritis.
    Scott DL; Kingsley GH
    N Engl J Med; 2006 Aug; 355(7):704-12. PubMed ID: 16914706
    [No Abstract]   [Full Text] [Related]  

  • 17. Switching biologics for psoriasis.
    Ormerod AD
    Br J Dermatol; 2010 Oct; 163(4):667-9. PubMed ID: 20854399
    [No Abstract]   [Full Text] [Related]  

  • 18. Emerging therapies in juvenile rheumatoid/idiopathic arthritis.
    Passo M
    Curr Probl Pediatr Adolesc Health Care; 2006 Mar; 36(3):97-103. PubMed ID: 16473286
    [No Abstract]   [Full Text] [Related]  

  • 19. [Intermittent treatment regimens and the rational (efficient) use of biologic agents in psoriasis].
    Moreno-Ramírez D
    Actas Dermosifiliogr; 2011 May; 102(4):241-3. PubMed ID: 21481332
    [No Abstract]   [Full Text] [Related]  

  • 20. Perioperative management of tumor necrosis factor antagonists in patients with psoriasis and other inflammatory disorders.
    Hession MT; Gottlieb AB
    J Dermatolog Treat; 2011 Apr; 22(2):90-101. PubMed ID: 20673155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.